NCT01606345View on ClinicalTrials.gov

Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Urothelial Carcinoma
Interventions
DRUG

Valrubicin

Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Endo Pharmaceuticals
All Listed Sponsors
collaborator

Endo Pharmaceuticals

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER